Author, Year | Country | Ethnicity | Disease | Adverse Effect | Assessment Criteria | SNP | MAF | Sample Size | EBRT Dose, Gy |
---|---|---|---|---|---|---|---|---|---|
Chang-Claude 2005 [40] | Germany | Caucasian | Breast cancer | Early effect: acute skin toxicity | RTOG/EORTC ≥ G2 | rs13181, rs1799793 | 0.378,0.368 | 441 | 50-60 |
Chang-Claude 2009 [41] | Germany | Caucasian | Breast cancer | Late effect: telangiectasia | RTOG/EORTC ≥ G2 | rs1799793 | 0.363 | 400 | 50-60 |
Duldulao 2013 [42] | USA | NR | Rectal cancer | Early effect: gastrointestinal and abdominal toxicity | CTCAE v3.0 ≥ G3 | rs13181 | 0.276 | 156 | 50.4-54 |
Fachal 2012 [43] | Spain | Caucasian | Prostate cancer | Early effect: gastrointestinal toxicity | CTCAE v2.0 ≥ G2 | rs1799793, rs1052555 | 0.342,0.328 | 698 | 70-76 |
Mangoni 2011 [44] | Italy | Caucasian | Breast cancer | Early effect: acute skin toxicity | CTCAE v2.0 ≥ G2ca | rs13181, rs1799793 | NA | 87 | 50-62.8 |
Raabe 2012 [45] | Germany | NR | Breast cancer | Early effect: acute skin toxicity | RTOG/EORTC ≥ G2 | rs13181 | 0.646 | 82 | 50.4 |
Sakano 2010 [46] | Japan | Asian | Bladder cancer | Early effect: diarrhea | CTCAE v3.0 ≥ G2 | rs13181 | NA | 93 | 30.0-60.4 |
Terrazzino 2012 [47] | Italy | Caucasian | Breast cancer | Early effect: acute skin toxicity | RTOG/EORTC ≥ G2 | rs13181 | 0.365 | 285 | 50-66 |
Yoon 2011 [48] | USA | Mixedb | Esophageal cancer | Early effect: esophageal toxicity and myelosuppression | RTOG/EORTC ≥ G3 | rs13181, rs1799793, rs1052555 | NA | 60 | 46 |
Zhang 2010 [49] | China | NR | Lung cancer | Early effect: esophageal toxicity | NR v2.0 ≥ G2 | rs13181 | 0.286 | 213 | 50-70 |
Zschenker 2010 [50] | Germany | NR | Breast cancer | Late effect: fibrosis | LENT/SOMA ≥ G2 | rs13181 | 0.551 | 69 | 54-55 |